AstraZeneca presents new data across continuum of care from its broad renal portfolio at ERA-EDTA 2020 Virtual Congress
AstraZeneca will present new data across its broad portfolio of renal medicines during the 57[th] European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, 6 to 9 June 2020. The 20 abstracts being presented, including four oral presentations, will include data on Lokelma (sodium zirconium cyclosilicate), roxadustat and Farxiga (dapagliflozin) across different stages of chronic kidney disease (CKD) and AstraZeneca’s ongoing commitment to exploring treatment options across the full continuum of renal care. Ruud Dobber, Executive Vice President,